After two years in the shadows, health stocks are back as a haven for investors navigating economic uncertainty.

Janus kinase (JAK) inhibitors look to be a good treatment option for the newly recognized, rare autoimmune disease known as ...

Switzerland-based pesticides maker Syngenta said on Wednesday that it has acquired a repository of natural compounds and ...

Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...

Legal notices were served on January 8 to three officials concerned including the Governor of the Bangladesh Bank (BB) urging to stay hand over share of Taka 230 crore of Novartis Bangladesh to Radian ...

Cash burn is likely to moderate going forward, as investments in Schrödinger's internal pipeline have now stabilized. Read ...

A federal court rejected Novartis Pharmaceuticals’, a unit of Novartis AG (NYSE:NVS) legal challenge to the Medicare Drug ...

If approved, Fabhalta® will be the only medicine indicated to selectively target the underlying cause of C3G1, an ultra-rare, progressive kidney disease with no currently approved treatments2-5 Phase ...

Rhumbline Advisers lowered its position in Novartis AG (NYSE:NVS – Free Report) by 14.0% during the fourth quarter, Holdings Channel reports. The institutional investor owned 34,754 shares of the ...

Novartis AG’s Sandoz family sold a roughly 1.2% stake in the Swiss pharmaceutical group for 2.6 billion Swiss francs ($2.9 ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Syngenta is continuing to grow its biologicals division with the recent acquisition of certain Novartis technologies.